La tecnología de reproducción asistida ayuda a abordar el problema demográfico en Europa (y 2)

[1] Grant J, Hoorens S, Sivadasan S, van het Loo M, DaVanzo J, Hale L, Gibson S, Butz W. Low fertility and population ageing: causes, consequences, and policy options - 2004. Disponible en http://www.rand.org/pubs/monographs/2004...

[2] Grant J, Hoorens S, Gallo F and Cave J - 2006. 'Should ART be part of a population policy mix? A preliminary assessment of the demographic and economic impact of Assisted Reproductive Technologies,' RAND, DB-507-FER, forthcoming via www.rand.org/publications.

[3] COMMUNICATION FROM THE COMMISSION; Green Paper 'Confronting demographic change; a new solidarity between the generations'.

[4] European Parliament Report on demographic challenges and solidarity between the generations (2005/2147(INI)).

[5] The European IVF-monitoring programme for the European Society of Human Reproduction and Embryology. Assisted reproductive technology in Europe, 2002. Results generated from European registers by ESHRE. Human Reproduction Advance Access published on April 3, 2006.

[6] European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilisation/intracytoplasmic sperm injection cycles: a randomised, comparative trial. Fertil Steril 2002; 78(3): 520-528.

[7] Data presented at ESHRE 2006. Srenson, P. Live birth rate in IVF cycles is significantly higher after stimulation with highly purified menotrophin compared with recombinant FSH, (Poster number 322, 19/06/2006).

Contacto: Greenhouse Communications, Lola Bhadmus - T: +44-(0)207-798-9925. Yvonne Mitchell - M: +44-(0)7790-001-959, E: kristin.o'leary@greenhouse-communications.com. O: RAND Europa - Oficina de prensa - Lynne Saylor: T: +44-(0)1223-273-898, E: saylor@rand.org